1
项与 JNJ-79032421 相关的临床试验 / Active, not recruiting临床1期 A Phase 1 Study of JNJ-79032421, a T-cell Redirecting Agent Targeting Mesothelin for Advanced Stage Solid Tumors
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).
100 项与 JNJ-79032421 相关的临床结果
100 项与 JNJ-79032421 相关的转化医学
100 项与 JNJ-79032421 相关的专利(医药)
100 项与 JNJ-79032421 相关的药物交易